Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M K Tuxen

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|August 23, 1993
[Localized nodular myositis--a focal form of myositis]M K Tuxen
Ugeskrift for Laeger|December 7, 1992
[Focal myositis]M K Tuxen, A Aru
Ugeskrift for Laeger|July 1, 1996
[Taxans in the treatment of ovarian cancer]M K Tuxen, P Dombernowsky
Cancer Treatment Reviews|April 1, 1994
Neurotoxicity secondary to antineoplastic drugsM K Tuxen, S W Hansen
Cancer Treatment Reviews|May 1, 1995
Tumor markers in the management of patients with ovarian cancerM K Tuxen, G Sölétormos, P Dombernowsky
Scandinavian Journal of Clinical and Laboratory Investigation|June 29, 2002
Serum tumor marker CA 125 for monitoring ovarian cancer during follow-upM K Tuxen, G Sölétormos, P Dombernowsky
British Journal of Cancer|May 18, 2001
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapyM K Tuxen, G Sölétormos, P Dombernowsky
Ugeskrift for Laeger|December 16, 1991
[Poisoning by kidney beans (Phaseolus vulgaris)]M K Tuxen, H V Nielsen, H Birgens
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Gemcitabine in the treatment of ovarian cancerS W Hansen, M K Tuxen, C Sessa
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
The role of second-look laparotomy in the long-term survival in ovarian cancerM K Tuxen, G Strauss, B Lund, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|August 23, 1993
[Localized nodular myositis--a focal form of myositis]M K Tuxen
Ugeskrift for Laeger|December 7, 1992
[Focal myositis]M K Tuxen, A Aru
Ugeskrift for Laeger|July 1, 1996
[Taxans in the treatment of ovarian cancer]M K Tuxen, P Dombernowsky
Cancer Treatment Reviews|April 1, 1994
Neurotoxicity secondary to antineoplastic drugsM K Tuxen, S W Hansen
Cancer Treatment Reviews|May 1, 1995
Tumor markers in the management of patients with ovarian cancerM K Tuxen, G Sölétormos, P Dombernowsky
Scandinavian Journal of Clinical and Laboratory Investigation|June 29, 2002
Serum tumor marker CA 125 for monitoring ovarian cancer during follow-upM K Tuxen, G Sölétormos, P Dombernowsky
British Journal of Cancer|May 18, 2001
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapyM K Tuxen, G Sölétormos, P Dombernowsky
Ugeskrift for Laeger|December 16, 1991
[Poisoning by kidney beans (Phaseolus vulgaris)]M K Tuxen, H V Nielsen, H Birgens
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Gemcitabine in the treatment of ovarian cancerS W Hansen, M K Tuxen, C Sessa
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
The role of second-look laparotomy in the long-term survival in ovarian cancerM K Tuxen, G Strauss, B Lund, et al.
Pageof 2